Preclinical Evaluation of a Bivalent Salmonella Typhi and Paratyphi A Vaccine

A 749.5 KB PDF document authored by Renzo Alfini, published on figshare under CC-BY-4.0 license and last updated on 2026-05-01. It describes preclinical studies for a bivalent conjugate vaccine targeting Salmonella Typhi and Paratyphi A, detailing its development, stability, and immunogenicity in animal models.

Use Cases

• Analyzing vaccine stability data based on the reported free O:2 antigen levels over one year
• Comparing immunogenicity results between conjugated and unconjugated polysaccharides as described in the preclinical models
• Evaluating conjugate chemistry selection criteria based on the described manufacturing simplicity, stability, and immunogenicity
• Supporting clinical trial design decisions based on the preclinical results that guided formulation selection

Strengths

• The document provides specific stability data, noting free O:2 antigen remained below 15% after 1 year of storage at 2–8 °C
• It details the specific conjugate chemistry (CDAP) and carrier protein (CRM197) used for both vaccine components
• The source is clearly attributed to an author (Renzo Alfini) and is openly licensed (CC-BY-4.0)

Limitations

• The dataset is a single PDF document (749.5 KB); the underlying raw experimental data (columns, rows) is not provided
• Row count and column-level documentation are unknown, limiting direct analysis of the primary data
• The temporal coverage of the data collection within the study is not specified

Provenance

Source

figshare, author Renzo Alfini

Collection Method

Likely contains results from laboratory experiments and animal model studies as described.

Freshness

Last updated 2026-05-01 05:27:23